Apellis Reveals Negative CHMP Opinion For Pegcetacoplan For GA In European Union And Plans To Seek Re-Examination Of Application
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its application for Pegcetacoplan for the treatment of geographic atrophy (GA) in the European Union. The company plans to request a re-examination of the application.
January 26, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock may face negative pressure in the short term due to the CHMP's negative opinion on its drug Pegcetacoplan for GA in the EU.
The negative opinion from CHMP is a significant regulatory hurdle for Apellis, potentially delaying or preventing market access in the EU for Pegcetacoplan. This can impact revenue projections and investor sentiment, likely leading to a decrease in stock price in the short term. The company's decision to seek re-examination may provide some hope, but the initial impact is negative.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100